In ALL, treatment with retinoid receptor agonists is able to fortify the sensitivity of IKZF1-aberrant BCR-ABL1 ALL patients to tyrosine kinase inhibitor therapy (Churchman et al., 2015). Here, IKZF1 is linked to acute lymphoblastic leukemia.